Handelsbanken Fonder’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Handelsbanken Fonder’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,732	Closed	-$584K	–	1587
2023 Q2	$584K	Sell	5,732 -2,500	-30%	-$237K	﹤0.01%	985
2023 Q1	$748K	Buy	8,232 +1,000	+14%	+$58.7K	﹤0.01%	808
2022 Q4	$275K	Buy	+7,232	New	+$249K	﹤0.01%	1295
2021 Q4	–	Sell	-5,900	Closed	-$594K	–	1771
2021 Q3	$594K	Hold	5,900	–	–	﹤0.01%	1239
2021 Q2	$835K	Buy	5,900 +800	+16%	+$90.3K	﹤0.01%	1027
2021 Q1	$508K	Hold	5,100	–	–	﹤0.01%	1191
2020 Q4	$630K	Sell	5,100 -1,800	-26%	-$237K	﹤0.01%	1033
2020 Q3	$672K	Sell	6,900 -20,000	-74%	-$2.5M	﹤0.01%	858
2020 Q2	$4.2M	Buy	26,900 +12,900	+92%	+$1.96M	0.04%	382
2020 Q1	$2.02M	Sell	14,000 -1,000	-7%	-$193K	0.04%	164
2019 Q4	$3.07M	Buy	+15,000	New	+$2.74M	0.05%	167

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Handelsbanken Fonder's RETA Position: Q3 2023 in Review

Handelsbanken Fonder sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 5,732 shares — an estimated $584K sold.

Handelsbanken Fonder first reported a position in RETA in Q4 2019 and held it in 11 quarters. The position peaked at $4.2M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Handelsbanken Fonder reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Handelsbanken Fonder sold 5,732 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $584K.
Handelsbanken Fonder first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 11 quarters.
Handelsbanken Fonder's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.2M in Q2 2020.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Handelsbanken Fonder's 13F filing for Q3 2023, filed 19 Oct 2023.